Creatio, The Centre for Production and Validation
of Advanced Therapies at the University of Barcelona
has obtained funding of almost €1 million
from the Ministry of Science and Innovation
to acquire and launch one of the first 4D bioprinters in the world.
Bioprinting involves the artificial manufacture
of human tissues by combining biomaterials and cells.
This technology is part of tissue engineering
and has led to a recent revolution both in the biomedical sector,
mainly focused on the generation of organs or artificial tissues with direct clinical application,
and in the pharmaceutical sector
focused on the creation of three dimensional cellular models.
Regenerative medicine is presenting great advances
to produce artificial tissues and organs.
However, a further step is needed
to produce artificial tissues and organs that can be implanted in patients.
The new bio printer will provide a
large number of solutions for the scientific and medical community.
We will be able to produce artificial skin for worms to different kinds of approaches
like minibrains for neurogenetic disorders.
Creatio's mission is focused on increasing the efficacy of the health system
to improve the quality of life of our society.
The new bioprinter opened a new era
of regenerative medicine to apply directly into the patient.
The bioprinter will be located in the creative facilities
with 300 sq m and four areas dedicated to the clinical production
of advanced therapists and medicinal products.
This bioprinter will position Creatio as a world leader in the manufacture
of tissues and organs for clinical application.
Creatio's next-generation bioprinter combines extrusion printing ejecting biological ink
with the use of lasers to guide the exact positioning of both
extracellular matter and the cells themselves.
Moreover, due to the gentle application of the laser, cells are bioprinted without stress,
improving their survival and allowing the creation of stress-sensitive tissues
such as the nervous system.
Innovation is the essence of the University of Barcelona.
As a consequence of this,
you are lived in the tissue regenerative medicine and as a proof of this scenario
they have now the possibility to work with the new bioprinter.
There are only another in the rest of the world.
With this new acquisition,
the University of Barcelona will contribute to the ultimate clinical application
of the artificial manufacture of tissues and organs,
providing a direct benefit to society and positioning itself at the forefront
of translational research in tissue engineering.